Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs

Pharmaceutical Research

Volumn 28, Issue 9, 2011, Pages 2339-2349

  Niwa, Toshiyuki ^a   Miura, Satoru ^a   Danjo, Kazumi ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

Dry nanosuspension; Nano milling; Redispersion; Solubilization; Spray drying

Indexed keywords

DODECYL SULFATE SODIUM; MANNITOL; NANOPARTICLE; PHENYTOIN; POVIDONE;

ANALYTIC METHOD; AQUEOUS SOLUTION; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRYSTALLIZATION; DISPERSION; DRUG SOLUBILITY; DRUG STABILITY; DRY NANOSUSPENSION; NANOANALYSIS; OSCILLATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SUSPENSION; WET MILLING TECHNIQUE; X RAY POWDER DIFFRACTION;

DRUG DESIGN; DRUG STABILITY; EQUIPMENT DESIGN; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POWDER DIFFRACTION; POWDERS; SOLUBILITY; SURFACE PROPERTIES; SUSPENSIONS; TECHNOLOGY, PHARMACEUTICAL; WATER; X-RAY DIFFRACTION;

EID: 80054759755     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0465-y     Document Type: Article

References (35)

1. Speiser PP. Poorly soluble drugs: a challenge in drug delivery. In: Müller RH, Benita S, Böhm B, editors. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific; 1998. p. 15-28.
2. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by seven UK-owned pharmaceutical companies. Br J Clin Pharmacol. 1988;25:387-96.
3. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Meth. 2000;44:235-49. (Pubitemid 32239479)
4. Lipinski CA. Poor aqueous solubility - An industry wide problem in drug discovery. Am Pharm Rev. 2002;5:82-5.
5. Schroter C. Prioritizing molecules based on physicochemical characteristics. Am Pharm Rev. 2006;9:60-7.
6. Amidon GL, Lennernas H, Shah VP, Crison JRA. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.
7. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharmaceutics. 2008;5(6):1003-19.
8. Janssens S, Anné M, Rombaut P, Van den Mooter G. Spray drying from complex solvent systems broadens the applicability of Kollicoat IR as a carrier in the formulation of solid dispersions. Eur J Pharm Sci. 2009;35:241-8.
9. Ahmed IS, Aboul-Einien MH. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin. Eur J Pharm Sci. 2007;32(1):58-68. (Pubitemid 47102190)
10. Gupta MK, Tseng YC, Goldman D, Bogner RH. Hydrogen bonding with adsorbent during storage governs drug dissolution from solid-dispersion granules. Pharm Res. 2002;19(11):1663-72. (Pubitemid 35305518)
11. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59:645-66. (Pubitemid 47299263)
12. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Controlled Release. 2007;123:78-99. (Pubitemid 47566400)
13. Kesisoglou F, Panmai S, Wu Y. Application of nanoparticles in oral delivery of immediate release formulations. Curr Nanosci. 2007;3:183-90. (Pubitemid 46845725)
14. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water soluble compounds. Toxicol Pathol. 2008;36:43-8.
15. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and "self-microemulsifying" drug delivery systems. Eur J Pharm Sci. 2000;11:93-8.
16. Gursoy RN, Benita S. Self emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58:173-82. (Pubitemid 38479922)
17. Niwa T, Miura S, Danjo K. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies-Development of particle design method. Int J Pharm. 2011;405:218-27.
18. Parikh D. Spray drying as a granulation technique. In: Parikh D, editor. Handbook of pharmaceutical granulation technology, drugs and the pharmaceutical sciences. New York: Marcel Dekker; 1997. p. 75-96.
19. Cal K, Sollohub K. Spray drying technique. I: Hardware and process parameters. J Pharm Sci. 2010;99(2):575-86.
20. Sollohub K, Cal K. Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci. 2010;99(2):587-97.
21. Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res. 1996;13(2):272-8. (Pubitemid 26074194)
22. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18:113-20. (Pubitemid 36184748)
23. Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, et al. Characterization of physicochemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm. 2007;338:198-206. (Pubitemid 46779149)
24. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. Drying of crystalline drug nanosuspensions - The importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci. 2008;35:127-35.
25. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van Den Mooter G. Alternative matrix formers for nanosuspension solidification: dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. Eur J Pharm Sci. 2008;35:344-53.
26. Jacobs C, Müller H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19(2):189-94. (Pubitemid 34165405)
27. Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm. 2006;64:360-8. (Pubitemid 44585201)
28. Junghanns JAH, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Inter J Nanomedicine. 2008;3(3):295-309.
29. Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S. Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders. Chem Pharm Bull. 2009;57(10):1050-7.
30. Kawabata Y, Yamamoto K, Debari K, Onoue S, Yamada S. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur J Pharm Sci. 2010;39(4):256-62.
31. Gulsun T, Gursoy RN, Oner L. Design and characterization of nanocrystal formulations containing ezetimibe. Chem Pharm Bull. 2011;59(1):41-5.
32. Tewa-Tagne P, Briançon S, Fessi H. Preparation of redispersible dry nanocapsules by means of spray-drying: Development and characterisation. Eur J Pharm Sci. 2007;30:124-35. (Pubitemid 46157175)
33. Grant DJW, Brittain HG. Solubility of pharmaceutical solids. In: Brittain HG, editor. Physical characterization of pharmaceutical solids, drugs and the pharmaceutical sciences, vol. 70. New York: Marcel Dekker; 1995. p. 321-86.
34. Pongpeerapat A, Wanawongthai C, Tozuka Y, Moribe K, Yamamoto K. Formulation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int J Pharm. 2008;352:309-16.
35. Moribe K, Wanawongthai C, Shudo J, Higashi K, Yamamoto K. Morphology and surface states of colloidal probucol nanoparticles evaluated by atomic force microscopy. Chem Pharm Bull. 2008;56(6):878-80. (Pubitemid 351872265)